Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 39Breast Neoplasms 24Neoplasms 12Prostatic Neoplasms 11Triple Negative Breast Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Fanconi Anemia, Complementation Group D1 5Small Cell Lung Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Solid Tumors 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Colorectal Neoplasms 2Carcinoma 2Advanced Solid Tumours 2Advanced Solid Tumor 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Metastatic Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1

Interventions

Bevacizumab 6Paclitaxel 5Leucovorin 5Irinotecan 5Fluorouracil 5napabucasin 4Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Ocoxin 3Imatinib Mesylate 3Drug Therapy 3palbociclib 2entinostat 2encorafenib 2Oxaliplatin 2Levoleucovorin 2Folfox protocol 2Everolimus 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2spartalizumab 1ribociclib 1repotrectinib 1pralsetinib 1pembrolizumab 1olaparib 1linifanib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Digestive System Neoplasms × olaparib × Clear all
NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Incyte Corporation

Phase 1 Recruiting
604 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡